JP2022531205A - 抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物 - Google Patents

抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物 Download PDF

Info

Publication number
JP2022531205A
JP2022531205A JP2021564373A JP2021564373A JP2022531205A JP 2022531205 A JP2022531205 A JP 2022531205A JP 2021564373 A JP2021564373 A JP 2021564373A JP 2021564373 A JP2021564373 A JP 2021564373A JP 2022531205 A JP2022531205 A JP 2022531205A
Authority
JP
Japan
Prior art keywords
rsv
patient
antigen
binding fragment
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021564373A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020223435A5 (https=
JP2022531205A5 (https=
Inventor
アーメド カーン，アニス
ピエール，バドリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2022531205A publication Critical patent/JP2022531205A/ja
Publication of JPWO2020223435A5 publication Critical patent/JPWO2020223435A5/ja
Publication of JP2022531205A5 publication Critical patent/JP2022531205A5/ja
Priority to JP2025014950A priority Critical patent/JP2025072444A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
JP2021564373A 2019-04-30 2020-04-30 抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物 Pending JP2022531205A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025014950A JP2025072444A (ja) 2019-04-30 2025-01-31 抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962840701P 2019-04-30 2019-04-30
US62/840,701 2019-04-30
PCT/US2020/030619 WO2020223435A1 (en) 2019-04-30 2020-04-30 Dosage regimens for and compositions including anti-rsv antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025014950A Division JP2025072444A (ja) 2019-04-30 2025-01-31 抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物

Publications (3)

Publication Number Publication Date
JP2022531205A true JP2022531205A (ja) 2022-07-06
JPWO2020223435A5 JPWO2020223435A5 (https=) 2023-05-11
JP2022531205A5 JP2022531205A5 (https=) 2023-05-11

Family

ID=70779897

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021564373A Pending JP2022531205A (ja) 2019-04-30 2020-04-30 抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物
JP2025014950A Pending JP2025072444A (ja) 2019-04-30 2025-01-31 抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025014950A Pending JP2025072444A (ja) 2019-04-30 2025-01-31 抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物

Country Status (15)

Country Link
US (3) US12024553B2 (https=)
EP (1) EP3962940A1 (https=)
JP (2) JP2022531205A (https=)
KR (1) KR20220002427A (https=)
CN (1) CN113825767A (https=)
AU (1) AU2020265676A1 (https=)
BR (1) BR112021020846A2 (https=)
CA (1) CA3138180A1 (https=)
CO (1) CO2021014370A2 (https=)
EA (1) EA202192776A1 (https=)
IL (1) IL287443A (https=)
MX (1) MX2021013248A (https=)
SG (1) SG11202111748TA (https=)
TW (1) TWI861099B (https=)
WO (1) WO2020223435A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI761453B (zh) * 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
WO2023039584A2 (en) * 2021-09-13 2023-03-16 Medimmune Limited Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018160722A1 (en) * 2017-03-01 2018-09-07 Medimmune Limited Anti-rsv monoclonal antibody formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
LT2950886T (lt) 2013-02-01 2020-07-10 Medimmune, Llc Respiracinio sincitinio viruso f baltymo epitopai
FR3008921B1 (fr) 2013-07-23 2015-12-25 Safran Piece en materiau composite avec portion de conductivite thermique et electrique et procede de fabrication d'une telle piece
EP4353316A3 (en) 2014-01-15 2024-08-21 Medimmune Limited Rsv-specific antibodies and functional parts thereof
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018160722A1 (en) * 2017-03-01 2018-09-07 Medimmune Limited Anti-rsv monoclonal antibody formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCI. TRANSL. MED., vol. vol.9, issue 388, JPN6024013561, 2017, pages 1928 - 1, ISSN: 0005426297 *

Also Published As

Publication number Publication date
EA202192776A1 (ru) 2022-01-19
JP2025072444A (ja) 2025-05-09
TWI861099B (zh) 2024-11-11
US20220204593A1 (en) 2022-06-30
CN113825767A (zh) 2021-12-21
WO2020223435A1 (en) 2020-11-05
TW202106333A (zh) 2021-02-16
CA3138180A1 (en) 2020-11-05
AU2020265676A1 (en) 2021-11-18
SG11202111748TA (en) 2021-11-29
BR112021020846A2 (pt) 2022-01-18
US20240417447A1 (en) 2024-12-19
US20200347120A1 (en) 2020-11-05
CO2021014370A2 (es) 2021-10-29
EP3962940A1 (en) 2022-03-09
KR20220002427A (ko) 2022-01-06
MX2021013248A (es) 2022-01-24
IL287443A (en) 2021-12-01
US12024553B2 (en) 2024-07-02

Similar Documents

Publication Publication Date Title
Huo et al. A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19
US20240417447A1 (en) Dosage regimens for and compositions including anti-rsv antibodies
IL262559A (en) Use of the il-17 antibody to prepare a drug for the treatment of atherosclerosis and psoriatic arthritis
JP7708860B2 (ja) 呼吸器合胞体ウイルスに特異的に結合する分子
TWI799417B (zh) 生物製藥組成物及相關方法
TW202304980A (zh) 經修飾的抗ｔｓｌｐ抗體
JP7467438B2 (ja) 抗ｒｓｖ抗体の製剤及びその使用方法
AU2022361501B2 (en) Anti-sars-cov-2 antibodies and uses thereof i
US20260092100A1 (en) Antibodies against metapneumovirus fusion (f) protein and uses thereof
AU2022361501A9 (en) Anti-sars-cov-2 antibodies and uses thereof i
Addetia et al. Potent neutralization of Marburg virus by a vaccine-elicited antibody
CN118524849A (zh) 用于治疗多血管炎、嗜酸性粒细胞增多综合症、伴有鼻息肉的慢性鼻窦炎嗜酸性粒细胞增多综合症(crswnp)或不伴有鼻息肉慢性鼻窦炎(crssnp)的白细胞介素5结合蛋白给药方案
EA046902B1 (ru) Схемы введения доз и композиции, включающие антитела к rsv
WO2023049501A1 (en) Compositions and methods for linear and conformational site specific antibodies and methods of making the same
RU2807524C2 (ru) Составы антител к rsv и способы их применения
US20250188153A1 (en) Hmpv antibodies and their use
CN120441690A (zh) 一种抗RSV和hMPV的抗体或其抗原结合片段和应用
WO2022079001A2 (en) Sars-cov-2 antigens, diagnostic and therapeutic uses
JP2024535009A (ja) ニルセビマブによる呼吸器合胞体ウイルス下気道感染の予防
TW202229333A (zh) 冠狀病毒結合分子及其使用方法
CN121426940A (zh) 特异性结合呼吸道合胞病毒的抗体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240704

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241001